Clinical evaluation of marketed and non-marketed orthodontic products: are researchers now ahead of the times? A meta-epidemiological study.

Industry funding Marketed products Orthodontics Randomised clinical trials

Journal

Progress in orthodontics
ISSN: 2196-1042
Titre abrégé: Prog Orthod
Pays: Germany
ID NLM: 100936353

Informations de publication

Date de publication:
23 Oct 2023
Historique:
received: 10 04 2023
accepted: 09 08 2023
medline: 26 10 2023
pubmed: 23 10 2023
entrez: 22 10 2023
Statut: epublish

Résumé

The advertisement and adoption of untested orthodontic products is common. This study aimed to provide an update regarding the prevalence of clinical trials in orthodontics evaluating commercially marketed products. Associations between marketed/non-marketed products and study characteristics such as direction of effect, declaration of conflict of interest and industry sponsorship were evaluated. In addition, within the marketed products associations between direction of effect and study characteristics were explored. Electronic searching of a single database (Medline via PubMed) was undertaken to identify Randomized controlled trials (RCTs) published over a 5-year period (1st January 2017 to 31st December 2021). Descriptive statistics and associations between trial characteristics were explored. 196 RCTs were analysed. RCTs were frequently published in Angle Orthodontist (18.4%), American Journal of Orthodontics and Dentofacial Orthopedics (14.8%) and European Journal of Orthodontics (13.3%). 65.3% (128/196) of trials assessed marketed products after their introduction. The majority of trials assessed interventions to improve treatment efficiency (33.7%). Growth modification appliances were typically analysed in non-marketed compared to marketed products. An association between the type of product (marketed vs non-marketed) and both the declaration of conflict of interest and industry sponsorship was detected. For individual RCTs assessing marketed products either a positive effect (45.3%) or equivalence between interventions or between intervention and untreated control (47.7%) was evident. In 27% of these trials either no conflict of interest or industry funding was not clearly declared. Within the marketed products, no association between the direction of the effect and conflict of interest or funding was detected. The analysis of marketed orthodontic products after their introduction is still common practice. To reduce research waste, collaboration prior to the licensing and marketing of orthodontic products between researchers, industry and manufacturers is recommended.

Sections du résumé

BACKGROUND BACKGROUND
The advertisement and adoption of untested orthodontic products is common. This study aimed to provide an update regarding the prevalence of clinical trials in orthodontics evaluating commercially marketed products. Associations between marketed/non-marketed products and study characteristics such as direction of effect, declaration of conflict of interest and industry sponsorship were evaluated. In addition, within the marketed products associations between direction of effect and study characteristics were explored.
MATERIAL AND METHODS METHODS
Electronic searching of a single database (Medline via PubMed) was undertaken to identify Randomized controlled trials (RCTs) published over a 5-year period (1st January 2017 to 31st December 2021). Descriptive statistics and associations between trial characteristics were explored.
RESULTS RESULTS
196 RCTs were analysed. RCTs were frequently published in Angle Orthodontist (18.4%), American Journal of Orthodontics and Dentofacial Orthopedics (14.8%) and European Journal of Orthodontics (13.3%). 65.3% (128/196) of trials assessed marketed products after their introduction. The majority of trials assessed interventions to improve treatment efficiency (33.7%). Growth modification appliances were typically analysed in non-marketed compared to marketed products. An association between the type of product (marketed vs non-marketed) and both the declaration of conflict of interest and industry sponsorship was detected. For individual RCTs assessing marketed products either a positive effect (45.3%) or equivalence between interventions or between intervention and untreated control (47.7%) was evident. In 27% of these trials either no conflict of interest or industry funding was not clearly declared. Within the marketed products, no association between the direction of the effect and conflict of interest or funding was detected.
CONCLUSIONS CONCLUSIONS
The analysis of marketed orthodontic products after their introduction is still common practice. To reduce research waste, collaboration prior to the licensing and marketing of orthodontic products between researchers, industry and manufacturers is recommended.

Identifiants

pubmed: 37867164
doi: 10.1186/s40510-023-00487-y
pii: 10.1186/s40510-023-00487-y
pmc: PMC10590772
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

32

Informations de copyright

© 2023. Italian Society of Orthodontics.

Références

Stat Med. 2010 Oct 15;29(23):2369-83
pubmed: 20687172
Am J Respir Crit Care Med. 2009 Sep 15;180(6):564-80
pubmed: 19734351
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
J Orthod. 2019 Jun;46(1_suppl):9-12
pubmed: 31056035
Angle Orthod. 2022 Mar 1;92(2):247-254
pubmed: 34878515
Int J Technol Assess Health Care. 1996 Spring;12(2):209-37
pubmed: 8707496
Nature. 2005 Jun 9;435(7043):737-8
pubmed: 15944677
Community Dent Oral Epidemiol. 1993 Feb;21(1):31-5
pubmed: 8432102
J Dent. 2020 Nov;102:103452
pubmed: 32805358
Prog Orthod. 2021 Dec 17;22(1):48
pubmed: 34918200
Clin Oral Investig. 2023 May;27(5):1851-1868
pubmed: 36879148
Prog Orthod. 2018 Jun 11;19(1):16
pubmed: 29888375
CMAJ. 2004 Feb 17;170(4):477-80
pubmed: 14970094
J Clin Epidemiol. 2017 Jul;87:78-86
pubmed: 28412465
Prog Orthod. 2017 Dec;18(1):14
pubmed: 28540615
BMC Oral Health. 2020 Sep 18;20(1):259
pubmed: 32948150
Sci Am. 2011 Jun;304(6):16
pubmed: 21608392
J R Soc Med. 2015 Mar;108(3):101-7
pubmed: 25389230
J Trauma. 2010 Sep;69(3):489-500
pubmed: 20838118
BMJ. 2002 Aug 3;325(7358):249
pubmed: 12153921
J Dent Res. 2021 Mar;100(3):245-252
pubmed: 33054504
Angle Orthod. 2008 May;78(3):574-5
pubmed: 18481405
Am J Orthod Dentofacial Orthop. 2014 Sep;146(3):279-85
pubmed: 25172249
Am J Orthod Dentofacial Orthop. 2021 Jul;160(1):77-83
pubmed: 33888376
Evid Based Med. 2017 Aug;22(4):139-142
pubmed: 28701372
Eur J Orthod. 2021 Oct 4;43(5):601-605
pubmed: 34184029
J Orthod. 2023 Jun;50(2):215-228
pubmed: 36550619
Am J Orthod Dentofacial Orthop. 2023 Feb;163(2):154-172
pubmed: 36464569
Spine J. 2011 Jun;11(6):471-91
pubmed: 21729796
J Law Med Ethics. 2012 Fall;40(3):452-66
pubmed: 23061573
Am J Orthod Dentofacial Orthop. 2022 Jan;161(1):20-36
pubmed: 34794862

Auteurs

Almaha Alhussain (A)

Department of Orthodontics, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, Floor 21, Guy's Hospital, Guy's and St Thomas NHS Foundation Trust, London, SE1 9RT, UK.

Martyn T Cobourne (MT)

Department of Orthodontics, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, Floor 21, Guy's Hospital, Guy's and St Thomas NHS Foundation Trust, London, SE1 9RT, UK.
Centre for Craniofacial Development and Regeneration, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, Floor 27, Guy's Hospital, Guy's and St Thomas NHS Foundation Trust, London, SE1 9RT, UK.

Nikolaos Pandis (N)

Department of Orthodontics and Dentofacial Orthopedics, Dental School/Medical Faculty, University of Bern, Bern, Switzerland.

Jadbinder Seehra (J)

Department of Orthodontics, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, Floor 21, Guy's Hospital, Guy's and St Thomas NHS Foundation Trust, London, SE1 9RT, UK. jadbinderpal.seehra@kcl.ac.uk.
Centre for Craniofacial Development and Regeneration, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, Floor 27, Guy's Hospital, Guy's and St Thomas NHS Foundation Trust, London, SE1 9RT, UK. jadbinderpal.seehra@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH